Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zepatier

- PMLiVE

Gilead posts strong data for all-oral hepatitis C treatment

Achieves sustained virologic response in 78 per cent of participants

- PMLiVE

Ligand/GSK’s Promacta cleared for hep C in US

New FDA approval is expected to open up a significant new market for the drug

- PMLiVE

J&J, Lilly and Merck join forces on clinical trials

Will set up database to improve efficiency of industry-sponsored drug trials

- PMLiVE

Merck & Co stops development of Januvia, atorvastatin combo

Company spokesperson claims decision is for “business reasons”

- PMLiVE

Boehringer launches online education portal for hepatitis C

Comes as company moves its interferon-free hep C regimen into phase III

- PMLiVE

UK to use GSK’s Rotarix in rotavirus vaccination programme

Chosen ahead of Merck & Co’s RotaTeq

- PMLiVE

Boehringer moves interferon-free hep C regimen into phase III

Oral combination drug achieved viral cure rate of up to 85 per cent in phase IIb

- PMLiVE

First Boehringer and now Merck ‘gamifies’ clinical research

Kaggle challenge set up to help pharma company develop safe and effective medicines

- PMLiVE

Merck misses revenue targets as Singulair slumps

Asthma drug hit hard by generic competition in the US

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

- PMLiVE

Merck & Co relocates global headquarters

Leaves Whitehouse Station for new site in New Jersey

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links